Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Grifols, S.A. logo

NASDAQ · GRFS

Grifols, S.A.

Healthcare · Drug Manufacturers - General

$8.10

Up+$0.06 (+0.75%)

Updated Nov 2, 2026, 10:02 AM

SID Score

5.9/10

Composite research score

Smart Money

56/100

Neutral

Market cap
7.74B
P/E ratio
24.94
Dividend yield
2.14%
52-week range
$6.96 – $9.77
Volume
803.38K
Avg. volume
623.71K

Price performance · GRFS

GRFS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

GRFS closed at $8.10 after 20 trading sessions, up 9.31% for the selected period.

Last close
$8.10
Period change
+9.31%
Period low
$7.17
Period high
$8.12
Daily close
View OHLC price history
GRFS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$8.10$8.2487$8.05$8.10803.38K
Oct 29, 2026$8.12$8.14$7.995$8.04273.39K
Oct 28, 2026$7.95$8.30$7.90$8.12969.08K
Oct 27, 2026$7.89$8.13$7.88$8.10840.52K
Oct 26, 2026$7.76$8.11$7.76$7.92845.89K
Oct 23, 2026$7.50$7.5688$7.4907$7.56992.34K
Oct 22, 2026$7.42$7.49$7.37$7.45482.55K
Oct 21, 2026$7.51$7.59$7.48$7.50310.9K
Oct 20, 2026$7.61$7.695$7.52$7.54369.08K
Oct 19, 2026$7.52$7.67$7.50$7.641.46M
Oct 16, 2026$7.59$7.75$7.57$7.64872.36K
Oct 15, 2026$7.51$7.56$7.40$7.54907.08K
Oct 14, 2026$7.29$7.40$7.22$7.24538.5K
Oct 13, 2026$7.36$7.36$7.15$7.17439.64K
Oct 12, 2026$7.52$7.52$7.36$7.37266.11K
Oct 9, 2026$7.51$7.53$7.44$7.46330.56K
Oct 8, 2026$7.42$7.45$7.2839$7.41368.07K
Oct 7, 2026$7.48$7.56$7.44$7.50260.7K
Oct 6, 2026$7.53$7.565$7.415$7.52326.1K
Oct 5, 2026$7.31$7.54$7.29$7.41492.77K

Latest GRFS news

The latest Smart Investors Daily articles mentioning GRFS.

Stock researchCompany · Overview

GRFS research

Overview

Company profile and research snapshot.

Company profile

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GRFS recent ratings
DateFirmRatingTarget
Sep 21, 2026BANCO SANTANDEROutperform—
Aug 17, 2026ALANTRA EQUITIESStrong Buy—
Jul 29, 2026ANALISIS BANCO SABADELLOverweight—
Jul 27, 2026BESTINVER SECURITIESBuy—
Jul 22, 2026CAIXABANK BPIBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Grifols (BME:GRF) Stock Still Looks Cheap Based On Current Earnings

Grifols has seen sharp swings over recent years, and that kind of ride naturally raises a blunt question for you as an investor: Does the current share price line up with what the business is actually earning today? The stock has fallen 44.9% over the past 5 years, which puts the spotlight firmly on whether the current valuation still lines up with its underlying earnings power. For a plasma focused healthcare group that relies heavily on converting collection capacity and manufacturing...

Yahoo · Oct 23, 2026

Plasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial Strength

White Falcon’s Q3 2026 letter reports 2.7% quarterly and 4.6% year-to-date net returns. The letter can be downloaded here. Management attributes the underperformance mainly to a sharp September pullback, rising interest rates, and zero energy exposure. The portfolio remains concentrated in contrarian, value-oriented holdings. White Falcon emphasizes reassessing investment theses as AI accelerates industry change, […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By